Experts / Advisory Board

sandra silbermann

Sandra Silbermann, B.A., Sc.M, Ph.D.

M.D. received from Cornell University Medical College. B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively. Postdoctoral training in hematology/oncology at the Brigham & Women's and the Dana Farber Cancer Institute in Boston. Career in clinical development started at Pfizer, Inc., supervising initiation of Tarceva ™ clinical trials. Project Leader for GleevecÒ - the innovative cancer drug developed by Novartis. Vice President of Oncology and Global Head of Translational Medicine in the newly formed Innovation division at Quintiles (overseeing drug development and novel technologies for new partnerships with the pharmaceutical and biotechnology industries). Highly experienced, well-esteemed oncologist, practicing as an attending physitian at Yale University Hospital and currently in the Hematology/Oncology clinic at the Duke VA in Durham, NC. Instructor in Medicine at Harvard Medical School.Member of Cancer Prevention and Research Institute of Texas. Winner of the clinical investigator award from the National Institue of Health. Author of patents. Senior Advisor in a numerous biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone, Roche.  Independent industry consultant for number of biotech companies.

donald picker

Donald H. Picker, Ph.D.

Received a doctorate from State University of New York at Albany. Expert with over 35 years of drug development experience, playing a leading role in due dilligence hundreds of drug cancidated in numerous therapeutic areas. He was responsible for development of Carboplatin, one of the world’s leading cancer drugs.

waldermar priebe

Waldemar Priebe, Ph.D.

Professor of Medical Chemistry at the Department of Experimental Therapeutics, Division of Cancer Medicine at the MD Anderson Cancer Center University of Texas in Houston. His research focuses on the design and development of new drugs with therapeutic potential in the field of oncology. A discoverer of five drugs with anticancer potential that are in various stages of clinical development and four drugs at the stage of preclinical studies. Author of over 200 publications and 60 patents.

See others